Cash is often biotech's most precious resource, but when a recession hits and capital markets seize up, it can be hard to come by.

Data presented at the 2012 International Liver Congress of the European Association for the Study of the Liver last month showed Gilead Sciences Inc.'s nuc drug GS-7977 works well with Bristol-Myers Squibb Co.'s NS5A inhibitor daclatasvir.

Drugs act on proteins, so it follows that protein activity would be most important in determining which patients are given a targeted cancer drug.

In conjunction with Eli Lilly and Co.'s recent FDA approval of Amyvid (florbetapir), Safeguard Scientifics Inc. received a $5.6 million earn-out payment from its investment in Avid Radiopharmaceuticals Inc. before Lilly purchased the biotech.

Inhaled asthma and chronic obstructive pulmonary disease (COPD) drugs act at the lung to improve breathing, but at supraoptimal doses, the drugs end up elsewhere in the body, potentially leading to undesirable side effects.

Last month, Anthera Pharmaceuticals Inc.'s Phase III VISTA-16 trial testing varespladib in acute coronary syndrome (ACS) patients was stopped for futility, a surprise considering the robust changes in biomarkers seen in the Phase II trial.

C3 Jian Inc. has found funding from an unusual place: Three Delta Dental member companies contributed $30 million to help the biotech develop C16G2, a peptide drug targeting the bacteria that cause dental cavities, and the rest of its oral health pipeline.

In 1998, Organogenesis Inc. received approval for its first allogeneic product, Apligraf, from the FDA's Center for Devices and Radiological Health (CDRH).

Correctly predicting the future is a necessary but difficult task for biotech executives. Making accurate forecasts about demographic trends, clinical data, regulatory decisions, competition, and prescription trends can guide where to allocate limited capital and even the timing on when to raise more.